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Point/Counterpoint FeindelPatients with aortic stenosis are rarely denied aortic valve re-
placement today, and with successful surgery they can ex-
pect excellent symptomatic relief and improved life
expectancy. However, after Shabudin Rahimtoola’s1 obser-
vation in 1978 that a prosthetic valve may not fully relieve
a patient’s aortic stenosis, a condition he referred to as
‘‘valve prosthesis–patient mismatch’’ (PPM), surgeons be-
came wary of the potential harm of inserting small valve
prostheses.1 Rahimtoola’s concerns were further supported
by the Framingham Study, as well as others, which showed
that patients with left ventricular hypertrophy had a reduced
life expectancy compared with those without left ventricular
hypertrophy.2,3 Because left ventricular hypertrophy does
not regress in patients with severe valve PPM, the natural
conclusion was that patients with PPM fare worse than those
who do not have mismatch. A number of studies have con-
firmed this to be the case, at least in the early postoperative
period, and particularly in those patients with poor ventricu-
lar function.4,5 Surgeons realized the risk of valve PPM
could be minimized if valves were implanted that provided
the patient with an effective valve orifice area of greater
than 0.85 cm2/m2. Since all mechanical and stented biopros-
theses are to some degree obstructive due to the presence of
sewing rings and stents, this is not always possible, espe-
cially in small patients. Tasca and colleagues6 showed that
more than 55% of patients in whom a 21-mm bioprosthetic
valve was inserted had either moderate or severe PPM, and
this figure increased to more than 90% in those who had
a 19-mm valve inserted.
Over time, a number of surgical techniques were devel-
oped to allow the insertion of appropriately sized prosthe-
ses, techniques described by Konno and colleagues,7
Nicks and colleagues,8 and Manouguian and Seybold-Ept-
ing.9 Although these techniques worked well, they also
added to the complexity of the surgery, especially in Konno
and colleagues’ procedure. This added complexity may
have contributed to a higher early perioperative mortality.10
Although this increased complexity and possible increased
mortality discouraged some surgeons from performing aor-
tic root enlargement, more recent series have shown that in
experienced hands aortic root enlargement does not in-
crease perioperative risk. Although there seems to be an
early survival benefit of avoiding PPM in these studies,
the long-term benefit of avoiding mismatch seems less
clear.11-13
In this series, reported by Dr Moon, 1399 patients who un-
derwent bioprosthetic AVR between 1992 and 2007 by 22
different surgeons were evaluated for early and late mortality
and the presence or absence of PPM. By using a ‘‘Social Se-
curity Death Index’’ to track long-term mortality, Dr Moon
observed that in patients aged less than 70 years the presence
of PPM was associated with impaired long-term survival.
However, this was not the case in patients aged more than
70 years. On the basis of these observations, he concluded
that ‘‘PPM had a negative impact on late survival for patients
less than or equal to 70 years of age, but for patients greater
than 70 years of age, PPM did not influence survival.’’ Al-
though not explicitly stated in this study, the obvious impli-
cation to surgeons is that aortic root enlargement techniques
are not necessary in elderly patients, especially if they think
they may be exposing their patients to an added risk during
aortic valve replacement.
Although Dr Moon observed that there was an association
between mortality and PPM, his analysis does not provide
sufficient information to define what that impact may be.
The main reason for this is his use of the Death Index Reg-
istry to identify mortality in this series. There was no re-
ported direct patient follow-up, which means that there is
no way of knowing the cause of death in any of the patients.
As a result, one cannot make any inference about the impact
of PPM on long-term survival in any of the groups. Follow-
ing Dr Moon’s methodology, it seems that in the older pa-
tients, 10-year survival was 42%  6% in those with
severe PPM compared with 29%  5% in those without
PPM, suggesting the unusual conclusion that severe PPM
actually conferred a survival benefit to the older patients!
This is highly unlikely to be the case and simply emphasizes
the inherent weakness of attempting to attach causation to an
isolated observation (in this case PPM) without identifying
the actual cause of death. Although Dr Moon makes some
interesting observations in this study, the reader must be cau-
tioned not to come to any conclusions about the influence
that PPM may or may not have on survival in any of the
groups studied in this series.
As cardiac surgeons, what should we do for the patient
with a small aortic annulus? Although most of us believe
that PPM is harmful to patients, we are unlikely to ever
see a randomized trial determining whether mismatch
reduces long-term survival. Consequently, we are left with
using indirect evidence to guide our practices. Because
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Feindel Point/Counterpointpatients with left ventricular hypertrophy do worse than
those without, and PPM after aortic valve replacement re-
sults in persistent left ventricular hypertrophy, most agree
that mismatch is not good for our patients. At the Toronto
General Hospital we discourage the use of small valves, es-
pecially 19-mm bioprosthetic valves. Whenever possible,
23-mm tissue valves for women and 25-mm tissue valves
for men are used, although 21 mm for women and 23 mm
for men are acceptable for elderly inactive individuals. To
adhere to these guidelines, aortic root enlargement is used
more than 75% of the time in my own practice.
Aortic root enlargement, whether Nicks and colleagues’
or Manouguian and Seybold-Epting’s procedure, is a valu-
able adjunct for the practicing cardiac surgeon, provided it
is performed well. By adhering to certain details, aortic
root enlargement can be performed safely and does not ap-
preciably add to the complexity of the surgery. One cannot
overemphasize that it is the meticulous attention to details
that will ensure the success of the procedure. I favor Nicks
and colleagues’ procedure, which extends the aortotomy in
the noncoronary sinus across the mitral annulus for no
more than 1 to 1.5 cm. Untreated autologous pericardium
(5 to 7-cm oval patch) is used to reconstruct this area using
a double suture layer (first a 4-0 followed by a 5-0 polypro-
pylene suture), which guarantees hemostasis in the critical
area that will be below the valve sewing ring. Pledgeted
valve sutures are placed around the annulus, and in the re-
gion of the patch these pledgets should be placed on the out-
side of the patch. In this area one should use large pledgets to
avoid tearing through the patch.14
There is an added advantage to the frequent use of aortic
root enlargement techniques. How often, after removal of
a heavily calcified aortic valve, are we left with a damaged
aortic annulus in which it will be difficult to implant a valve
prosthesis? How often do we encounter difficulties in safely
closing the aortic wall of a rigid calcified aortic in a frail el-
derly person? Surgeons facile with the use of pericardial
patches, whether bovine or autologous, to enlarge the aortic
root are usually very comfortable with reconstruction tech-
niques required to manage these unexpected yet not uncom-
mon situations.
No doubt some surgeons will continue to advocate that
a safely performed aortic valve replacement using a small
valve is better than adding the potential risk of an aortic route
enlargement procedure. However, they must also accept that
these patients will almost certainly leave the operating room
with PPM along with its potential harmful consequences.The Journal of Thoracic and CIn the end, it will be up to the individual surgeon to balance
the risk of performing an aortic root enlargement procedure
with the risk of PPM. My own view is that aortic root
enlargement is a reproducible procedure that can safely be
performed by any surgeon performing aortic valve surgery.
Young trainees are eager to learn aortic root enlargement
techniques, and those who are comfortable with routine
aortic valve replacement should have no difficulty in per-
forming them under supervision. In our University of
Toronto Cardiac Surgery Residency Program we make
every effort to ensure that trainees are provided with such
opportunities by mentors who are comfortable with aortic
root enlargement techniques.
Dr Moon’s research, although interesting, has not con-
vinced me that we can ignore PPM in any patient group re-
gardless of age. In my opinion, size indeed does matter!
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